Summary
CA 19-9 is a protein that is often raised in pancreatic cancer and cancers of the bile ducts and gallbladder. It is used mainly to support diagnosis in people with relevant symptoms or findings, and to monitor treatment and detect recurrence — not to screen healthy people, as it can be raised by benign conditions and is normal in some cancers.
CA 19-9 is most useful in the assessment and monitoring of pancreatic and biliary tract cancers. In someone with suspected pancreatic cancer, a markedly raised CA 19-9 supports the diagnosis alongside imaging, and the level can carry prognostic information.
It is not a screening test. CA 19-9 is raised in many benign conditions — particularly those causing bile duct obstruction, such as gallstones and jaundice — as well as in other gastrointestinal cancers. Importantly, a small proportion of people (those who are Lewis antigen negative) do not produce CA 19-9 at all, so it can be falsely normal.
In people with diagnosed pancreatic or biliary cancer, serial CA 19-9 levels help monitor treatment response and detect recurrence, with the trend over time being most informative.
What It Is
CA 19-9 (sialyl-Lewis A) is a carbohydrate antigen expressed on glycoproteins and glycolipids of pancreatic and biliary epithelium. Its synthesis depends on the Lewis blood group enzyme, so the 5–10% of people who are Lewis-negative cannot produce CA 19-9, limiting its use in that group.
CA 19-9 is elevated in most pancreatic cancers and in biliary tract cancers, but also in benign biliary obstruction (where jaundice itself raises it), pancreatitis, and other gastrointestinal cancers. This lack of specificity, and its insensitivity in early disease, mean it is not suitable for screening.
Reference range: approximately < 37 U/mL, varying by laboratory. Very high levels suggest malignancy and may indicate more advanced disease; benign obstruction can also produce significant elevations that fall once the obstruction is relieved.
Functions
Pancreatic and biliary cancer support
Supports the diagnosis of pancreatic and biliary tract cancers alongside imaging in symptomatic people.
Treatment monitoring
Tracks response to treatment — falling CA 19-9 suggests response, rising levels suggest progression.
Recurrence detection
A rising CA 19-9 after treatment can indicate recurrence, prompting further imaging.
Prognostic information
Very high levels can indicate more advanced disease and a poorer prognosis.
Reference Ranges
CA 19-9
Measured in U/mL| Status | Range (U/mL) | Range (kU/L) | What it means |
|---|---|---|---|
| Normal | < 37 | Within normal range — does not exclude cancer (and is always normal in Lewis-negative people). | |
| Mildly raised | 37–100 | Mild elevation — often benign (e.g. biliary obstruction, pancreatitis); interpret with imaging. | |
| Elevated | > 100 | Significantly raised — increases concern for pancreatic or biliary cancer; investigate. |
CA 19-9 is not a screening test. Benign biliary obstruction raises it; 5–10% of people cannot produce it at all. Reference ranges vary by laboratory. Interpret with imaging, bilirubin, and the clinical picture.
Symptoms of Imbalance
CA 19-9 is measured when pancreatic or biliary cancer is suspected; the marker itself causes no symptoms.
- A normal CA 19-9 is reassuring but does not exclude cancer
- Always normal in Lewis-antigen-negative individuals
- Jaundice (yellowing of skin and eyes)
- Abdominal or back pain
- Unexplained weight loss
- Loss of appetite
- Pale stools and dark urine (biliary obstruction)
- Often no symptoms in early disease
Causes of Imbalance
- Normal in healthy people
- Lewis-antigen-negative status (cannot produce CA 19-9)
- Effective cancer treatment (falling CA 19-9)
- Pancreatic cancer
- Biliary tract and gallbladder cancer
- Benign biliary obstruction and jaundice (gallstones)
- Pancreatitis
- Other gastrointestinal cancers (colorectal, gastric)
- Liver disease
FAQs
No. CA 19-9 is not suitable for screening healthy people. It is often normal in early pancreatic cancer, can be raised by benign conditions such as gallstones and jaundice, and cannot be produced at all by the 5–10% of people who are Lewis-antigen negative. Its proper role is to support diagnosis in symptomatic people, alongside imaging, and to monitor known disease.
CA 19-9 is produced by the lining of the pancreas and bile ducts, and is cleared in bile. Anything that obstructs the bile ducts — most commonly gallstones causing jaundice — backs up this clearance and raises CA 19-9, sometimes markedly. Pancreatitis and liver disease can also elevate it. Such elevations typically fall once the underlying problem, like a blockage, is relieved.
A normal CA 19-9 does not rule out cancer. Around 5–10% of people are Lewis-antigen negative and cannot produce CA 19-9 at all, so it will always read low for them regardless of disease. Some cancers also do not raise it, especially early on. This is why CA 19-9 is interpreted alongside imaging, other tests, and the clinical picture rather than relied on alone.
In a person diagnosed with pancreatic or biliary cancer that produces CA 19-9, the level is measured before and during treatment. A falling CA 19-9 suggests the cancer is responding, while a rising level can indicate progression or recurrence. Tracking the trend over time provides useful information to guide treatment decisions, complementing imaging and clinical assessment.
References
- Locker GY, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327. View source
- Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma. J Gastrointest Oncol. 2012;3(2):105–119. View source
- Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–270. View source